Business Context and Reporting Period
Company: BillionToOne, Inc. (BLLN)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: BillionToOne is a precision diagnostics company utilizing a single-molecule next-generation sequencing (smNGS) platform. Its primary revenue streams are prenatal screening (UNITY) and oncology liquid biopsy (Northstar) tests. The company is an emerging growth company and a non-accelerated filer.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 |
Six Months Ended June 30, 2026 |
|---|---|---|
| Revenue | $109,448 | $217,836 |
| Gross Profit | $77,107 | $156,203 |
| Gross Margin | 70.5% | 71.7% |
| Net Income (Loss) | $8,054 | $26,024 |
| Operating Income (Loss) | $5,503 | $23,337 |
| Cash and Cash Equivalents | $548,628 (Balance Sheet) | $548,628 (Balance Sheet) |
| Long-Term Debt | $91,031 | $91,031 |
| Working Capital | $595,651 | $595,651 |
Note: Working Capital calculated as Total Current Assets ($651,376) minus Total Current Liabilities ($55,725).
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 64.4% quarter-over-quarter (QoQ) and 73.5% year-over-year (YoY) for the six-month period. This was driven by a 35% increase in test volume (196,000 tests in Q2 2026 vs. 145,000 in Q2 2025) and a 21% increase in Average Selling Price (ASP).
- Profitability: The company achieved net income of $8.1 million for the quarter, compared to a net loss of $0.2 million in the prior year quarter. Operating income turned positive at $5.5 million, up from a loss of $1.6 million.
- Expense Increases: Operating expenses rose significantly due to headcount expansion. Selling, General, and Administrative (SG&A) expenses increased 62.8% QoQ, and Research and Development (R&D) expenses increased 47.3% QoQ.
- Debt Activity: Long-term debt increased from $57.2 million to $91.0 million following the mandatory draw of a $30.0 million third tranche under the Oberland Capital Note Purchase Agreement on March 31, 2026.
- Non-GAAP Adjustments: Significant non-cash charges impacted GAAP results, including $8.2 million in stock-based compensation and a $3.0 million loss on the change in fair value of the term loan for the quarter.
Guidance, Outlook, and Risks
- Product Pipeline: The company launched "Unity Confirm" (a non-invasive confirmation assay) in May 2026 and announced a 130-gene panel expansion for the Unity Fetal Risk Screen in August 2026. In oncology, new tests including Northstar PGx, Northstar Select CH, and Northstar Origin were launched or announced in early-to-mid 2026. A pan-cancer MRD test is expected in Q4 2026.
- Operational Expansion: The company is expanding laboratory capacity with a new 220,000 sq. ft. facility in Austin, Texas (occupancy expected 2027) and a 62,659 sq. ft. oncology-dedicated facility in Union City, CA (occupancy expected 2027).
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2026, due to unremediated material weaknesses. These include insufficient resources for financial reporting, lack of segregation of duties, and ineffective controls over financial instruments (warrants and debt).
- Legal Proceedings: Illumina, Inc. filed a lawsuit on May 7, 2026, alleging patent infringement regarding the UNITY test. BillionToOne is vigorously defending the claim and does not believe a loss is probable.
- Liquidity: Management believes current cash and cash equivalents ($548.6 million) are sufficient to fund operations for at least the next 12 months.
Investor Verification Checklist
- Remediation of Material Weaknesses: Verify the progress and timeline for fixing the internal control deficiencies regarding financial instruments and segregation of duties.
- Debt Covenants: Monitor compliance with the Oberland Capital revenue and gross margin covenants, which require trailing six-month net revenue to reach $120.0 million by year-end 2026.
- Reimbursement Trends: Assess the sustainability of the 21% ASP increase and the impact of new payor contracts on future cash collections, given the $33.3 million increase in accounts receivable.
- Legal Exposure: Track the status of the Illumina patent infringement lawsuit and potential impacts on the UNITY product line.
- Non-GAAP Reconciliation: Review the reconciliation of GAAP to Non-GAAP metrics, specifically the treatment of the fair value changes in the term loan and stock-based compensation.